4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 6.4% – Time to Sell?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s share price fell 6.4% during trading on Monday. The stock traded as low as $13.06 and last traded at $12.7930. 144,943 shares traded hands during trading, a decline of 83% from the average daily volume of 845,019 shares. The stock had previously closed at $13.67.

Wall Street Analyst Weigh In

FDMT has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Bank of America increased their price target on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday, September 29th. Cantor Fitzgerald raised shares of 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price target for the company in a report on Monday, September 14th. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. Finally, Chardan Capital lowered their price objective on shares of 4D Molecular Therapeutics from $26.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.90.

4D Molecular Therapeutics Stock Down 2.8%

The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. The company has a market capitalization of $693.81 million, a P/E ratio of -4.78 and a beta of 2.75. The company has a 50 day moving average of $13.61 and a 200-day moving average of $11.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The business had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. As a group, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.07 EPS for the current year.

Insider Transactions at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider David Kirn sold 58,333 shares of the firm’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $13.90, for a total transaction of $810,828.70. Following the completion of the transaction, the insider owned 767,486 shares of the company’s stock, valued at approximately $10,668,055.40. This trade represents a 7.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 134,570 shares of company stock valued at $1,743,197 in the last ninety days. 7.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several large investors have recently made changes to their positions in the business. Sei Investments Co. boosted its stake in 4D Molecular Therapeutics by 8.9% during the 1st quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock valued at $120,000 after purchasing an additional 1,050 shares during the last quarter. Headlands Technologies LLC increased its position in shares of 4D Molecular Therapeutics by 20.6% during the 2nd quarter. Headlands Technologies LLC now owns 19,238 shares of the company’s stock valued at $256,000 after purchasing an additional 3,282 shares during the last quarter. Legal & General Group Plc bought a new position in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $59,000. Susquehanna Fundamental Investments LLC purchased a new position in 4D Molecular Therapeutics during the second quarter valued at $148,000. Finally, The Manufacturers Life Insurance Company purchased a new position in 4D Molecular Therapeutics during the second quarter valued at approximately $166,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.